Presented on Monday, October 19, 2009 in Atlanta, Georgia

Reproductive endocrinologists and fertility specialists have several options for patients undergoing luteal support for in vitro fertilization. How has luteal support evolved in recent years, and how will it be done in the future? Elena H. Yanushpolsky, MD, and Brian Berger, MD, discuss results of their research comparing efficacy of IM progesterone, vaginal tablets, and vaginal gel. Paul Zarutskie, MD, discusses the effect of additional research on a meta-analysis that has influenced the use of progesterone in fertility treatments.

This webcast was supported by Columbia Laboratories.

Elena H. Yanushpolsky, MD
Obstetrics Gynecology and Reproductive Biology
Brigham and Women’s Hospital
Harvard University School of Medicine
Boston, Mass.
For Dr Yanushpolsky’s presentation, click here

Brian Berger, MD
Director, Donor Egg and Gestational Carrier Program
Boston IVF
Assistant Clinical Professor
Harvard University School of Medicine
Waltham, Mass.
For Dr Berger’s presentation, click here

Paul Zarutskie, MD
Zarutskie Consulting Group
Seattle, Wash.
For Dr Zarutskie’s presentation, click here

Crinone^® 8% (progesterone gel) is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency.

The most common side effects of Crinone^® 8% include breast enlargement, constipation, somnolence, nausea, headache, and perineal pain. Crinone^® 8% is contraindicated in patients with active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thomboembolic disorders, missed abortion, undiagnosed vaginal bleeding, liver dysfunction or disease, and known or suspected malignancy of the breast or genital organs.

For full prescribing information, click here.